Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
Michael Boyiadzis, Mei-Jie Zhang, Karen Chen, Hisham Abdel-Azim, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Talha Badar, Sherif M Badawy, Minoo Battiwalla, Nelli Bejanyan, Vijaya Raj Bhatt, Valerie I Brown, Paul Castillo, Jan Cerny, Edward A Copelan, Charles Craddock, Bhagirathbhai Dholaria, Miguel Angel Diaz Perez, Christen L Ebens, Robert Peter Gale, Siddhartha Ganguly, Lohith Gowda, Michael R Grunwald, Shahrukh Hashmi, Gerhard C Hildebrandt, Madiha Iqbal, Omer Jamy, Mohamed A Kharfan-Dabaja, Nandita Khera, Hillard M Lazarus, Richard Lin, Dipenkumar Modi, Sunita Nathan, Taiga Nishihori, Sagar S Patel, Attaphol Pawarode, Wael Saber, Akshay Sharma, Melhem Solh, John L Wagner, Trent Wang, Kirsten M Williams, Lena E Winestone, Baldeep Wirk, Amer Zeidan, Christopher S Hourigan, Mark Litzow, Partow Kebriaei, Marcos de Lima, Kristin Page, Daniel J Weisdorf
No abstract text is available yet for this article.
March 22, 2023: Leukemia
#2
JOURNAL ARTICLE
Michael J Mauro, Timothy P Hughes, Dong-Wook Kim, Delphine Rea, Jorge E Cortes, Andreas Hochhaus, Koji Sasaki, Massimo Breccia, Moshe Talpaz, Oliver Ottmann, Hironobu Minami, Yeow Tee Goh, Daniel J DeAngelo, Michael C Heinrich, Valle Gómez-García de Soria, Philipp le Coutre, Francois-Xavier Mahon, Jeroen J W M Janssen, Michael Deininger, Naranie Shanmuganathan, Mark B Geyer, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Matthias Hoch, Fabian Lang
Asciminib is approved for patients with Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (CML-CP) who received ≥2 prior tyrosine kinase inhibitors or have the T315I mutation. We report updated results of a phase 1, open-label, nonrandomized trial (NCT02081378) assessing the safety, tolerability, and antileukemic activity of asciminib monotherapy 10-200 mg once or twice daily in 115 patients with CML-CP without T315I (data cutoff: January 6, 2021). After ≈4-year median exposure, 69...
March 22, 2023: Leukemia
#3
JOURNAL ARTICLE
Dieter Weichenhan, Anna Riedel, Charlotte Meinen, Alisa Basic, Reka Toth, Marion Bähr, Pavlo Lutsik, Joschka Hey, Etienne Sollier, Umut H Toprak, Simge Kelekçi, Yu-Yu Lin, Mariam Hakobyan, Aurore Touzart, Ashish Goyal, Justyna A Wierzbinska, Matthias Schlesner, Frank Westermann, Daniel B Lipka, Christoph Plass
No abstract text is available yet for this article.
March 22, 2023: Leukemia
#4
JOURNAL ARTICLE
Pooja S Kumar, Tracy Wiczer, Lindsay Rosen, Arthur J Pollauf, Amy Zheng, Marilly Palettas, Leylah Azali, Seema A Bhat, John C Byrd, Michael R Grever, Kerry A Rogers, Jennifer A Woyach, Adam S Kittai
Acalabrutinib is a next-generation, more selective, covalent Bruton tyrosine kinase inhibitor (BTKi), designed to have less toxicity, including bleeding, than the first-generation covalent BTKi ibrutinib. We performed a retrospective medical record review of 289 patients with B-cell malignancies treated with acalabrutinib to evaluate and describe bleeding events. Median acalabrutinib exposure was 40.8 months (range 0-81.6) with 83% of patients experiencing at least one bleeding event. Of these patients, 59%, 35%, and 6% had a clinically non-relevant minor, clinically relevant minor, or major bleed as their first, most severe event per ISTH criteria, respectively...
March 17, 2023: Leukemia
#5
JOURNAL ARTICLE
Kyoo-Hyung Lee, Suk Ran Yoon, Jeong-Ryeol Gong, Eun-Ji Choi, Hun Sik Kim, Chan-Jeoung Park, Sung-Cheol Yun, Soo-Yeon Park, Sol-Ji Jung, Hanna Kim, Soo Yun Lee, Haiyoung Jung, Jae-Eun Byun, Mirang Kim, Seon-Young Kim, Jeong-Hwan Kim, Je-Hwan Lee, Jung-Hee Lee, Yunsuk Choi, Han-Seung Park, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Jimin Woo, Hyeran Kang, Seunghyun Baek, Su Mi Kim, Hoon-Min Kim, Kwang-Hyun Cho, Inpyo Choi
Clinical effect of donor-derived natural killer cell infusion (DNKI) after HLA-haploidentical hematopoietic cell transplantation (HCT) was evaluated in high-risk myeloid malignancy in phase 2, randomized trial. Seventy-six evaluable patients (aged 21-70 years) were randomized to receive DNKI (N = 40) or not (N = 36) after haploidentical HCT. For the HCT conditioning, busulfan, fludarabine, and anti-thymocyte globulin were administered. DNKI was given twice 13 and 20 days after HCT...
March 17, 2023: Leukemia
#6
JOURNAL ARTICLE
Daniel Moreno Berggren, Hege Garelius, Petter Willner Hjelm, Lars Nilsson, Bengt Rasmussen, Caroline E Weibull, Mats Lambe, Sören Lehmann, Eva Hellström-Lindberg, Martin Jädersten, Elisabeth Ejerblad
In this population-based study, we aimed to characterize and compare subgroups of therapy-related Myelodysplastic syndromes (t-MDS) and define the implications of type of previous treatment and primary disease. We combined data from MDS patients, diagnosed between 2009 and 2017 (n = 2705), in the nationwide Swedish MDS register, with several health registers. Furthermore, using matched population controls, we investigated the prevalence of antecedent malignancies in MDS patients in comparison with the general population...
March 17, 2023: Leukemia
#7
JOURNAL ARTICLE
Elisa Bianchi, Sebastiano Rontauroli, Lara Tavernari, Margherita Mirabile, Francesca Pedrazzi, Elena Genovese, Stefano Sartini, Massimiliano Dall'Ora, Giulia Grisendi, Luca Fabbiani, Monica Maccaferri, Chiara Carretta, Sandra Parenti, Sebastian Fantini, Niccolò Bartalucci, Laura Calabresi, Manjola Balliu, Paola Guglielmelli, Leonardo Potenza, Enrico Tagliafico, Lorena Losi, Massimo Dominici, Mario Luppi, Alessandro Maria Vannucchi, Rossella Manfredini
Clonal myeloproliferation and development of bone marrow (BM) fibrosis are the major pathogenetic events in myelofibrosis (MF). The identification of novel antifibrotic strategies is of utmost importance since the effectiveness of current therapies in reverting BM fibrosis is debated. We previously demonstrated that osteopontin (OPN) has a profibrotic role in MF by promoting mesenchymal stromal cells proliferation and collagen production. Moreover, increased plasma OPN correlated with higher BM fibrosis grade and inferior overall survival in MF patients...
March 16, 2023: Leukemia
#8
JOURNAL ARTICLE
Eileen Wedge, Ulvi Ahmadov, Thomas B Hansen, Zongliang Gao, Morten Tulstrup, Christophe Côme, Sridhar Nonavinkere Srivatsan, Tanzir Ahmed, Jakob S Jespersen, Balthasar C Schlotmann, Claudia Schöllkopf, Klas Raaschou-Jensen, Niels Ødum, Jørgen Kjems, Rasmus O Bak, Matthew J Walter, Kirsten Grønbæk, Lasse S Kristensen
Mutations in U2AF1 are relatively common in myelodysplastic neoplasms (MDS) and are associated with an inferior prognosis, but the molecular mechanisms underlying this are not fully elucidated. Circular RNAs (circRNAs) have been implicated in cancer, but it is unknown how mutations in splicing factors may impact on circRNA biogenesis. Here, we used RNA-sequencing to investigate the effects of U2AF1 mutations on circRNA expression in K562 cells with a doxycycline-inducible U2AF1S34 mutation, in a mouse model with a doxycycline-inducible U2AF1S34 mutation, and in FACS-sorted CD34+ bone marrow cells from MDS patients with either U2AF1S34 or U2AF1Q157 mutations...
March 15, 2023: Leukemia
#9
JOURNAL ARTICLE
Engraftment in NSG SCF mice correlates with the WHO category and prognosis in systemic mastocytosis.
Michael Willmann, Barbara Peter, Katharina Slavnitsch, Daniela Berger, Nadine Witzeneder, Gabriele Stefanzl, Gregor Eisenwort, Daniel Ivanov, Irina Sadovnik, Emir Hadzijusufovic, Georg Greiner, Tina Bernthaler, Gregor Hoermann, Maik Dahlhoff, Thomas Rülicke, Peter Valent
No abstract text is available yet for this article.
March 14, 2023: Leukemia
#10
JOURNAL ARTICLE
Marine Armand, Michaël Degaud, Bruno Tesson, Cécile Laurent, Manon Vavasseur, Mélanie Parisot, Bénédicte Hoareau-Coudert, Danielle Canioni, Jean Marie Michot, Frédéric Charlotte, Véronique Meignin, Camille Laurent, Alexandra Traverse-Gléhen, Diane Damotte, Emmanuel Bachy, Caroline Besson, Olivier Hermine, Frédéric Davi, Lucile Couronné
No abstract text is available yet for this article.
March 13, 2023: Leukemia
#11
JOURNAL ARTICLE
Kate Manos, Geoffrey Chong, Colm Keane, Sze-Ting Lee, Charmaine Smith, Leonid Churilov, Joseph McKendrick, William Renwick, Piers Blombery, Melinda Burgess, Niles Elizabeth Nelson, Tineke Fancourt, Joanne Hawking, Wendi Lin, Andrew M Scott, Allison Barraclough, Joel Wight, Andrew Grigg, Chun Yew Fong, Eliza A Hawkes
Immune evasion, due to abnormal expression of programmed-death ligands 1 and 2 (PD-L1/PD-L2), predicts poor outcomes with chemoimmunotherapy in diffuse large B-cell lymphoma (DLBCL). Immune checkpoint inhibition (ICI) has limited efficacy at relapse but may sensitise relapsed lymphoma to subsequent chemotherapy. ICI delivery to immunologically intact patients may thus be the optimal use of this therapy. In the phase II AvR-CHOP study, 28 patients with treatment-naive stage II-IV DLBCL received sequential avelumab and rituximab priming ("AvRp;" avelumab 10 mg/kg and rituximab 375 mg/m2 2-weekly for 2 cycles), R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone for 6 cycles) and avelumab consolidation (10 mg/kg 2-weekly for 6 cycles)...
March 11, 2023: Leukemia
#12
JOURNAL ARTICLE
J L Ramdial, B C Valdez, B S Andersson, Y Nieto
No abstract text is available yet for this article.
March 11, 2023: Leukemia
#13
JOURNAL ARTICLE
Sarah A Carratt, Garth L Kong, Cody Coblentz, Zachary Schonrock, Lauren Maloney, Ben Weeder, Will Yashar, Rowan Callahan, Hunter Blaylock, Colin Coleman, Dan Coleman, Theodore P Braun, Julia E Maxson
No abstract text is available yet for this article.
March 9, 2023: Leukemia
#14
JOURNAL ARTICLE
Yusuke Kiyoki, Takayasu Kato, Sakura Kito, Takashi Matsuzaka, Shin Morioka, Junko Sasaki, Kenichi Makishima, Tatsuhiro Sakamoto, Hidekazu Nishikii, Naoshi Obara, Mamiko Sakata-Yanagimoto, Takehiko Sasaki, Hitoshi Shimano, Shigeru Chiba
No abstract text is available yet for this article.
March 8, 2023: Leukemia
#15
REVIEW
Giovanni Barosi, Vittorio Rosti, Robert Peter Gale
In this Perspective, we discuss criteria for defining a new disease entity or variant of a recognized disease or disorder. We do so in the context of the current topography of the BCR::ABL-negative myeloproliferative neoplasms (MPNs) where two new variants are reported: clonal megakaryocyte dysplasia with normal blood values (CMD-NBV) and clonal megakaryocyte dysplasia with isolated thrombocytosis (CMD-IT). The cardinal feature of these variants is bone marrow megakaryocyte hyperplasia and atypia corresponding the WHO histological criteria for primary myelofibrosis (myelofibrosis-type megakaryocyte dysplasia-MTMD)...
March 4, 2023: Leukemia
#16
EDITORIAL
Malgorzata Dawidowska, Agnieszka Dzikiewicz-Krawczyk, Natalia Rozwadowska, Panagiotis Ntziachristos, Joost Kluiver, Anke van den Berg, Reiner Siebert, Maciej Giefing
No abstract text is available yet for this article.
March 3, 2023: Leukemia
#17
EDITORIAL
Victor Hoffbrand, Robin Foà
No abstract text is available yet for this article.
March 3, 2023: Leukemia
#18
JOURNAL ARTICLE
Romy Kronstein-Wiedemann, Sarah Blecher, Madeleine Teichert, Laura Schmidt, Jessica Thiel, Markus M Müller, Jörn Lausen, Richard Schäfer, Torsten Tonn
The ABO blood group (BG) system is of great importance for blood transfusion and organ transplantation. Since the same transcription factors (TFs) and microRNAs (miRNAs) govern the expression of ABO BG antigens and regulate erythropoiesis, we hypothesized functional connections between both processes. We found significantly higher hemoglobin and hematocrit values in BG B blood donors compared to BG A. Furthermore, we observed that erythropoiesis in BG B hematopoietic stem/progenitor cells (HSPCs) was accelerated compared to BG A HSPCs...
February 28, 2023: Leukemia
#19
JOURNAL ARTICLE
Kari Hemminki, Janne Hemminki, Asta Försti, Amit Sud
Studies of survival in hematological malignancies (HMs) have generally shown an improvement over time, although most of these studies are limited by a short follow-up period. Using the NORDCAN database with data from Denmark, Finland, Norway and Sweden, we follow periodic increases in relative survival in seven HMs through half a century up to 2015-2019. Five-year survival improved in all seven HMs, reaching 90% for Hodgkin lymphoma (HL), myeloproliferative neoplasias and chronic lymphocytic leukemia (CLL), 60% for multiple myeloma (MM) and chronic myeloid leukemias (CMLs), 50% for the myelodysplastic syndromes and 30% for acute myeloid leukemia (AML)...
February 24, 2023: Leukemia
#20
JOURNAL ARTICLE
Frank Stegelmann, Lino L Teichmann, Florian H Heidel, Carl C Crodel, Thomas Ernst, Sebastian Kreil, Andreas Reiter, Sara Otten, Stefanie Schauer, Ruth-Miriam Körber, Kim Kricheldorf, Susanne Isfort, Hartmut Döhner, Tim H Brümmendorf, Martin Griesshammer, Konstanze Döhner, Steffen Koschmieder
No abstract text is available yet for this article.
February 24, 2023: Leukemia
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
